SignalXSignalX

ARWR ARROWHEAD PHARMACEUTICALS, INC.

FY2025 10-K
Filed: Nov 25, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
ARROWHEAD PHARMACEUTICALS, INC. Overview

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed its fiscal year 2025 10-K annual report with the SEC on Nov 25, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business: RNA interference (RNAi) therapeutics silencing disease-causing genes via proprietary TRiM delivery platform
  • • New commercial product: REDEMPLO® (plozasiran) FDA approved in 2025 for Familial Chylomicronemia Syndrome (FCS)
+3 more insights

Management Discussion & Analysis

  • • Cash, cash equivalents, short-term investments sufficient for near-term needs as of Sept 30, 2025
  • • Capital expenditures $12.5M in 2025, $136.9M in 2024 for manufacturing facility build-out; $0.1M more expected
+3 more insights

Risk Factors

  • • Regulatory risk from FDA clinical trial authorizations for ARO-DM1 affecting milestone payments ($100M milestone triggered Nov 2025)
  • • Geopolitical risk limited; primary macro exposure through $500M upfront from Sarepta and $200M from Novartis licensing agreements in FY 2025
+3 more insights

Financial Summary
XBRL

Revenue

$829M

Net Income

-$2M

Operating Margin

11.9%

Net Margin

-0.2%

ROE

-0.3%

Total Assets

$1.4B

EPS (Diluted)

$-0.01

Operating Cash Flow

$180M

Source: XBRL data from ARROWHEAD PHARMACEUTICALS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on ARROWHEAD PHARMACEUTICALS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available